

Jean Hoffman-Censits

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5731737/publications.pdf>

Version: 2024-02-01

28
papers

7,470
citations

623734

14
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

9417
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	13.7	3,077
2	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	13.7	1,728
3	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. <i>Cancer Cell</i> , 2014, 25, 152-165.	16.8	1,358
4	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 68, 959-967.	1.9	395
5	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 525-537.	10.7	225
6	Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1094.	7.1	205
7	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nature Communications</i> , 2017, 8, 2193.	12.8	99
8	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020, 203, 690-698.	0.4	76
9	Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1335-1339.	7.0	70
10	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2021, 79, 364-371.	1.9	41
11	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	4.1	39
12	Recent developments in the treatment of advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 109-114.	1.6	34
13	Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e521-e524.	1.9	18
14	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. <i>European Urology Oncology</i> , 2021, 4, 297-300.	5.4	18
15	Chemotherapy and Targeted Therapies: Are We Making Progress in Castrate-Resistant Prostate Cancer?. <i>Seminars in Oncology</i> , 2013, 40, 361-374.	2.2	15
16	Understanding Psychosocial and Sexual Health Concerns Among Women With Bladder Cancer Undergoing Radical Cystectomy. <i>Urology</i> , 2021, 151, 145-153.	1.0	13
17	A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 81, 138-142.	1.9	12
18	Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4089-4098.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. , 2020, 8, e000419.		7
20	Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. Clinical Genitourinary Cancer, 2021, 19, 176-181.	1.9	7
21	New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer “ What do we understand so far?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 619-622.	1.6	7
22	Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. Clinical Genitourinary Cancer, 2022, 20, 60-68.	1.9	6
23	Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 127-135.	1.2	5
24	Combination immunotherapy in genitourinary malignancies. Current Opinion in Urology, 2016, 26, 523-528.	1.8	4
25	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e15-788.e21.	1.6	2
26	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of Clinical Oncology, 2014, 32, 4171-4172.	1.6	1
27	Reply by Authors. Journal of Urology, 2020, 203, 697-698.	0.4	0
28	Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0